Roy H Larsen

This inventor holds 3 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Anticancer Therapeutic Inventions as. Active years: 2003-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roy H Larsen. Retrieved from https://idiyas.com/inventor/roy-h-larsen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 3 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 50(Granted Patents)

Company Filing History:

3 out of 3

Anticancer Therapeutic Inventions as

patents

Years Active: 2003-2004

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6740304 - Receptor binding conjugates (2004-05-25),

2. 6635234 - Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning (2003-10-21),

3. 6592843 - Radioactive therapeutic liposomes (2003-07-15),

Title: The Innovative Contributions of Roy H. Larsen

Introduction

Roy H. Larsen is a notable inventor based in Bekkestua, Norway. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 3 patents, Larsen's work focuses on advanced therapeutic methods that target calcified tissues.

Latest Patents

Larsen's latest patents include groundbreaking developments in receptor binding conjugates. His work on the preparation and use of radium-223 aims to target calcified tissues for pain palliation and bone cancer therapy. Additionally, he has described processes for the preparation and use of radium-223 for the treatment of calcified tumors, bone tumors, and the conditioning of bone surfaces and soft tissues.

Career Highlights

Throughout his career, Larsen has been dedicated to advancing cancer therapies. His innovative approaches have the potential to improve treatment outcomes for patients suffering from bone-related cancers. His expertise in this area has established him as a key figure in the field of therapeutic inventions.

Collaborations

Larsen has collaborated with esteemed colleagues such as Gjermund Henriksen and Øyvind S. Bruland. These partnerships have further enhanced the impact of his work in cancer treatment.

Conclusion

Roy H. Larsen's contributions to cancer therapy through his innovative patents demonstrate his commitment to improving patient care. His work continues to pave the way for advancements in the treatment of bone cancer and related conditions.

Profile summary based on public USPTO records.